In-vitro and in-vivo evaluation of the antistaphylococcal activity of S-5556, a new 16-membered macrolide by Chuard, C. et al.
Journal of Antimicrobial Chemotherapy (1992) 30, 327-337
In-vitro and in-vivo evaluation of the antistaphylococcal activity of
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Division of Infectious Diseases, University Hospital, CH-1211, Geneva 4, Switzerland
During recent years, a resurgence of interest in the macrolides had led to the
discovery of new derivatives of erythromycin with improved antibacterial activity
and pharmacokinetic properties. In this study the in-vitro and in-vivo antistaphylo-
coccal activity of S-5556, a 16-mciubered macrolide, was evaluated. In vitro, S-5556
was slightly less active than erythromycin against methicillin-susceptible
Staphylococcus aureus. In contrast, it had superior activity for methicillin-rcsistant
S. aureus (MRSA); several of these strains with inducible resistance to the macro-
lides-tincosamides-streptogramins group were susceptible to S-5556 whereas erythro-
mycin was inactive. The combination of S-5556 with oxacillin was synergic for most
MRSA strains tested. In vivo, a single prophylactic dose of S-5556 prevented
75%-100% of the cases of acute staphylococcal subcutaneous foreign body infec-
tion in a guinea pig-model. In a rat-model of chronic implant infection due to a
methiciUin- and erythromycin-resistant S. aureus strain, S-5556 significantly
decreased the bacteria] concentration around the foreign material, however resistant
mutants emerged.
Introduction
Erythroroycin has been used as an effective and safe antimicrobial agent for nearly four
decades. Its spectrum includes numerous Gram-positive bacteria, among them
staphylococci (Steibigcl, 1990). During the past few years, a resurgence of interest in the
macrolides has led to the discovery of several 14-, IS-, and 16-membered derivatives of
erythromycin with improved properties (Kirst & Sides, 1989a,A). S-5556 (para-
nitrobenzyl-oxime-tylosine) is one of the 16-membered compounds descnbed recently
(Ruggeri et at., 1989). This study examined S-5556 in vitro and in vivo as an antistaphy-
lococcal agent First, its inhibitory activity, alone or in combination with other
antibiotics, was evaluated against a collection of clinical isolates including methicillin-
susceptible and -resistant Staphylococcus aureus and coagulate-negative staphylococci.
Secondly, S-5556 was tested as a prophylactic agent in a guinea pig-model of acute
subcutaneous foreign body infection caused by a methicillin- and crythromycin-
susceptible strain of S. aureus (Zimmerli et al., 1982; Tshefu, Zimmerli & Waldvogel,
1983; Bouchenaki et al., 1990; Vaudaux et al., 1990), and as a therapeutic agent in a
rat-model in which a methicillin- and erythromycin-resistant S. aureus strain was
responsible for a chronic implant infection (Lucet et al., 1990; Chuard et al., \99\a,b).
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Table L Comparative in-vitro activity of S-5556 and other antistaphylococcal agents for
S. aweus and coagulase-negative staphyloccod
Organism
(no. of strains)
Methicillin-susceptible
S. aweus (23)
Methkillin-resistant
S. aweus (17)
Coagulase-negative
staphylococci (16)
Agent
S-5556
erythromycin
roxithromycin
penicillin
oxacillin
gentamicin
rifampicin
vancomycin
fleroxacin
ofloxacin
S-5556
erythromycin
roxithromycin
penicillin
oxacillin
gentamicin
rifampicin
vancomycin
fleroxacin
ofloxacin
S-5556
erythromycin
roxithromycin
penicillin
oxacillin
gentamicin
rifampicin
vancomycin
fleroxacin
ofloxacin
50%
1
025
05
05
025
025
O008
1
05
025
2
32
32
>16
32
025
O008
1
05
025
1
025
025
05
025
003
0008
2
05
025
MIC (mg/L)
90%
1
05
05
2
1
025
O008
2
05
025
>32
>32
>32
>16
>32
>32
0008
2
05
025
>32
>32
>32
8
32
16
0015
2
1
025
Range
025-2
025-8
025-32
O03-2
012-1
012-32
0004-1
1-2
025-05
012-025
l->32
025-> 32
O5->32
>16
8->32
O12->32
O004->012
1-2
05
025-05
O5->32
025->32
O12->32
O03->16
O06->32
003- > 32
0004-0015
2
05-8
025-1
Methods
Antimicrobial agents
Antibiotic powder of S-5556 was kindly provided by Servier (Neuilly-sur-Seine,
France) and the other tested antimicrobials listed in Table I by their respective
manufacturers. S-5556 was dissolved in water and the other agents in solvents as
recommended by their manufacturers.
Bacteria
Staphylococcus spp. were selected from a collection of blood culture-isolates of patients
with proven septicaemia associated with intravenous device infection. Methicillin-
resistant 5. aweus (MRSA) were chosen from a collection described previously
(Hemmer, Vaudaux & Waldvogel, 1979; Vaudaux & Waldvogel, 1979). All strains were
identified to species level with the API 32 Staph strip (API System, Montalieu-Vercieu,
France).
16-membered macrolides for stapfaylococcal infections 329
Susceptibility testing
The MICs of each agent for the staphylococci were determined with the agar dilution
method recommended by the National Committee for Clinical Laboratory Standards
(NCCLS, 1990). The inocula were prepared in 0-9% NaCl from three to five colonies of
overnight cultures and were adjusted to a turbidity equivalent to that of a McFarland
05 standard, corresponding to c. 10* cfu/mL. With a multipoint inoculating device
(Cathra, MCT Diagnostics, MN, USA), 1 /iL of this inoculum was transferred to the
surface of the antibiotic-containing Mueller-Hinton agar (Oxoid, Hampshire, UK).
The final inoculum on the plates was 104 to lO'cfu/spot.
The plates were incubated in air at 35CC for 20 h, and thereafter were read by eye.
The MIC of the antimicrobial was defined as the lowest concentration that completely
inhibited growth, ignoring a faint haze of growth.
Microorganisms were screened for resistance to erythromycin with discs containing
erythromycin (15 /xg) or clindamycin (2 ng). Blunting of the clindamycin zone near the
erythromycin disc was an indication of inducible resistance to the macrolide-
lincosamides-streptogramins group ( = inducible resistance to erythromycin); when no
inhibition zone was seen around either antibiotic discs, resistance was considered to be
constitutive.
Antibiotic combination studies
S-5556 was combined with the antimicrobials listed in Table m and evaluated with the
chequerboard technique using a plate microdilution assay and Mueller-Hinton broth
(Oxoid).
After an incubation of 20 h at 35°C the plates were read and the fractional inhibitory
concentration (FIQ index determined. The FIC was defined as the lowest concentra-
tion of each of the two tested antimicrobials that had an inhibitory effect when acting
together divided by the MIC of that drug alone, the sum of the FICs of the two
antimicrobials being the FIC index. The tested antimicrobial combinations were
interpreted as synergic when the FIC indices were < 0-5, additive when 0-5-0-75,
indifferent when 1-4, and antagonistic when > 4 (Krogstag & Mocllering, 1986).
Prophylaxis of acute foreign body infection in guinea pigs
Four polytetrafluoroethylene (Teflon) multiperforated tissue cages containing three
polymethylmethacTylate (Plexiglas) coverslips were implanted subcutaneously in each
guinea pig as previously described (Zimmerli et al., 1982). Three weeks later, after full
healing of the incision, the animals were used for pharmacokinetic and prophylaxis
studies.
The pharmacokinetic study was performed by taking blood (n = 3) 1, 3, 6 and 10 h
and tissue cage fluid (n = 8) 3, 6, 10, 14, 24 and 36 h after the administration of
100 mg/kg (single dose) of S-5556 intraperitoneally to the guinea pigs. Concentrations
of the drug in the serum and cage fluid were determined by a microbiological agar
diffusion assay with Micrococcus luteus NCTC 8340.
In the prophylaxis study, tissue cages were checked for sterility and inoculated with
0-1 mL of saline containing c. 10J or 103cfu of S. aureus Wood 46, a methicillin-,
erythromycin- and S-5556-susceptible strain (MIC of S-5556: 2 mg/L); this was done
6 h after the injection of S-5556, to ensure a concentration of drug above the MIC in all
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cages at the time of inoculation. Without prophylactic treatment, 102 cfu are known to
produce an infection in > 95% of the cages and 103cfu regularly infect all the cages
(Zimmerli et al., 1982). Quantitative cultures were performed 24, 48 h and seven days
after inoculation by plating 0-1 mL of tissue cage fluid, undiluted and ten-fold serially
diluted, on Mueller-Hinton agar. The detection limit was lOcfu/mL. No significant
carry-over of antibiotic was observed by using these experimental conditions. Agar
plates were read after 48 h of incubation at 37°C. On day 7, tissue cages were removed
under strict aseptic conditions and coverslips were extracted from the cages, sonicated
and cultivated in 5 mL of Mueller-Hinton broth and observed for one week. Control
animals underwent the same procedure without receiving the drug. Results of prophy-
laxis with S-5556 were compared with those obtained with vancomycin in a previous
study (Bouchenaki et al., 1990). In that study, vancomycin had been administered as a
single dose of 30 mg/kg, with peak and 24-h tissue cage fluid concentrations of 50-fold
and eight-fold the MIC, respectively.
Treatment of chronic foreign body infection in rats
As guinea pigs spontaneously expel infected subcutaneous foreign bodies after one to
two weeks and rapidly suffer from severe diarrhoea under antimicrobial treatment, a
model of chronic tissue cage infection was developed in rats, which allows more
prolonged periods of therapy (Lucet et al., 1990). At three weeks after implantation,
sterile tissue cages were injected with 1-5 x 103 cfu of S. aureus MRGR3, a methicillin-,
gentamicin- and erythromycin-resistant, but S-5556-susceptible (MIC = 2 mg/L)
clinical isolate. Three weeks later, tissue cages containing > 1 x lO^cfu/mL of fluid
( > 90%) were included in the pharmacokinetic and therapeutic protocols.
The pharmacokinetics of S-5556 were studied in 12 tissue cages after administration
of the drug at a dosage of 100 mg/kg intraperitoneally every 24 h for four days. Drug
concentrations were measured by bioassay on samples taken 1, 3, 6, 10, 14 and 24 h
after injection.
In the therapeutic protocol, chronically infected rats received S-5556 for six days.
Quantitative cultures of tissue cage fluid (0-1 mL, ten-fold serially diluted, incubation
for 48 h at 37°Q was performed on day one (before first dose) and day 7 (24 h after last
dose) and expressed as loglocfu/mL. The detection limit was 100 cfu/mL but was never
reached. No significant antibiotic carry-over occurred. At the end of treatment,
resistant mutants to S-5556 were searched for by plating 0-1 mL of 1/5 diluted cage
fluid on Mueller-Hinton agar plates containing S-5556 at a concentration of 10 mg/L.
S. aureus isolates which were found to be resistant to S-5556 were fully characterized
by biochemical tests (API 32 Staph strip), susceptibility testing to a large panel of
antibiotics, serotyping and phage typing.
As in the prophylactic study, results were compared with those of a control,
untreated, group and with the results of a previous study (Lucet et al., 1990) where
vancomycin was used (50 mg/kg twice a day for six days; peak concentration on day
four 15-fold the MIC, though concentration: seven-fold the MIC).
Statistics
In the prophylaxis protocol, the efficacy of S-5556 in reducing colony counts below the
detection limit was compared with controls by chi-square test with Yates' correction. In
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Table IL Comparative in-vitro activity of macrolides and oxacillin for Staphylococcus spp.
classified according to their susceptibility to erythromycin
Organism
(no. of strains) Agent 50%
MIC (mg/L)
90% Range
Erythromycin-susceptible
staphylococci (34)
Staphylococci with
induciWe resistance
to erythromycin (13)
Staphylococci with
constitutive resistance
to erythromycin (9)
S-5556
erythromycin
roxithromycin
oxacillin
S-5556
erythromycin
roxithromycin
oxacillin
S-5556
erythromycin
roxithromycin
oxacillin
1
0-25
05
025
1
16
32
32
>32
>32
>32
32
2
05
05
4
2
>32
>32
>32
>32
>32
>32
>32
025-2
025-05
O12->32
O06->32
1-2
4->32
4->32
025-> 32
>32
32->32
>32
O12->32
the therapeutic protocol, the mean changes in bacterial counts between day 1 and 7
under S-5556 and without treatment were compared with Student's f-test (two-tailed).
Results
In-vitro studies
The inhibitory activity of the macrolides S-5556, erythromycin and roxithromycin as
well as seven other antistaphylococcal agents on 56 Staphylococcus spp. is shown in
Table I. For methicillin-susceptible S. aureus, the MICs of S-5556 were generally twice
the value of those obtained for erythromycin and roxithromycin. For MRSA the MIC,,
of all macrolides were > 32 mg/L. Nine of fifteen isolates moderately or highly
resistant to erythromycin (MIC 4 mg/L; in three and MIC > 8 mg/L in 12) were
inhibited by < 2 mg/L of S-5556; these nine isolates showed an inducible-type resist-
ance to the macrolide-lincosomide-streptogramin group. When the 56 staphylococci
were classified according to their susceptibility to erythromycin all isolates with
inducible resistance to erythromycin were susceptible to S-5556, whereas those having
constitutive resistance to erythromycin were also resistant to S-5556 (Table II).
The combination of S-5556 with vancomycin was indifferent except for one isolate
where it was additive (Table III). The effect of combining S-5556 with oxaciUin varied
from indifference to synergy and was strain dependent. For oxacillin-susceptible
isolates (MIC < 4 mg/L) the combination was indifferent or additive (FIC index
> 0-5), but for oxacillin-resistant isolates (MIC < 4 mg/L) the combination acted
synergically (FIC index < 05). The statistical evaluation of this observation for 21
Staphylococcus spp. (12 MRSA) revealed statistical significance (P<04)5) when
applying Fisher's exact test (two-tailed). The inhibitory activity of S-5556 was reduced
by the quinolone ofloxacin such that in 2/7 tested isolates an FIC index of > 4, an
antagonistic effect, was observed. The combination S-5556 plus rifampicin was usually
additive and strain-dependent, but there was no relationship between these results and
a particular subgroup of staphylococci.
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Figure 1. Prophyiaxil of foreign body infection in guinea pigs. Phannacolrinetici of a single intraperitoseal
dose of 100 mg/kg S-5556 in serum (O) and tissue cage fluid ( • ) .
Prophylaxis of acute foreign body infection in guinea pigs
After a single dose of 100 mg/kg, the mean peak serum concentration of S-5556 in
guinea pigs was found to be 13-54 mg/L after 3 h. The concentration in the tissue cage
fluid was above the MIC from 4 to 28 h following administration, reaching maximal
values of 4-23 ±2-11 mg/L (mean±s.D.) after 10 h (Figure 1).
Twenty-four hours after a challenge of 102 cfu of S. aureus Wood 46, 11/15 (73%)
tissue cage fluids yielded no bacteria on culture; after 48 h, 15/15 were culture negative,
a proportion which underwent no change after seven days. Culture of coverslips, placed
in the cages as a control to exclude survival of small subpopulations of adherent
bacteria, was negative in all cases; the direct culture of coverslips is the most sensitive
procedure to assume that the foreign body is sterile. After the injection of 103 bacteria,
the number of negative fluids was 4/8 (50%) at 24 h, 7/8 (88%) at 48 h and 6/8 (75%) at
seven days, and 6/8 (75%) coverslips were sterile when removed. All cultures were
positive at all times for the control group (P < 0-0001). These results are similar to
those obtained in a recent study with vancomycin using exactly the same protocol
(Bouchenaki et al., 1990); at that time, the coverslips were not cultured (Table IV).
Treatment of chronic foreign body infection in rats
After four doses of 100 mg/kg of S-5556 in rats, the peak and trough levels in tissue
cage fluid were 6-46± 1-35 mg/L and 4-19±0-85 mg/L, respectively (Figure 2).
At the beginning of treatment, bacterial counts of S. aureus MRGR3 in the tissue
cage fluid were 6-78±l-051og|0cfu/mL, with no statistically significant differences
between the group receiving S-5556, the control group and a group of animals recently
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Figure 2. Treatment of foreign body infection in rats. Phannacoltinettc* after four intraperitoneal doses
every 24 h of S-5556 in tissue cage fluid.
treated with vancomycin using exactly the same protocol (Lucet et al., 1990). As shown
in Table V, viable bacterial counts decreased l-35±l-201og10cfu/mL in cage fluid of
rats treated for one week with S-5556, which was significantly more than in the control
group (0-01 ±0-96 logl0cfu/mL decrease, P < 0-001) but in the range of the results
previously obtained with vancomycin (l-16±f>59 logl0cfu/mL decrease) (Lucet et al.,
1990).
In animals treated with S-5556, bacteria resistant to high concentrations
( > 128 mg/L) of this antibiotic were found in small numbers (417 x 10~3-2-73 x 10~5)
in 4/14 cages on day 7. Their biochemical pattern, serotype and phage type were similar
to those of MRGR3. Except for resistance to S-5556, the susceptibility to antibiotics in
the mutants was similar to that of MRGR3 in one case and there was the additional
appearance of a resistance to clindmaycin in the three other cases.
Table V. Efficacy of S-5556 and vancomycin in the treatment of chronic tissue cage infection due
to S. mtreus MRGR3 in rats
Antibiotic Dose (mg/kg) No.
Mean decrease (S.D.) of bacterial counts
in tissue cage fluid after six days
of treatment (logl0 cfu/mL)
None 15 0-01 (096)
S-5556
None*
Vancomycin'
100, once-daily
50, bd
14
27
16
1-35 (1-20)
020 (084)
116 (059)
/»<O001
•Published data (Lucet et al., 1990).
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Discussion
In vitro, S-5556 was slightly less active than erythromycin for methicillin-susceptible
S. aureus. Other authors have observed similar results when several 16-membered
macrolides (josamycin, spiramycin, miocamycin and rokitamycin) were compared with
erythromycin (Fernandes & Hardy, 1988). In contrast, MRSA were more often
susceptible to S-5556 than to erythromycin due to the fact that in this group numerous
strains had inducible resistance to erythromycin. Staphylococci with this type of
resistance were uniformly susceptible to S-5556 in our study, and have previously been
reported to be susceptible to other 16-membered macrolides (Fernandes & Hardy,
1988; Hardy et al., 1988) while showing resistance to 14- and 15-membered macrolides
(such as erythromycin, roxithromycin, clarithromycin, azithromycin, dirithromycin and
flurithromycin). This property makes 16-membered macrolides an attractive antibiotic
class for the treatment of staphylococcal infections.
Among the different antimicrobial agents tested in combination with S-5556, only
oxacillin was synergic and this effect was observed significantly more often with MRSA
than with strains susceptible to oxacillin. A similar synergic phenomenon on MRSA
has already been described with the combination of quinolones and oxacillin (Rohner
et al., 1989). It has been shown that quinolones enhance the binding of oxacillin to
penicillin-binding protein (PBP) 2' in MRSA (Lucain, Furet & Pechere, 1991). Whether
macrolides improve the activity of oxacillin by a similar mechanism remains to be
studied.
Antistaphylococcal prophylaxis for surgical procedures involving the insertion of
foreign material currently relies on the use of two bactericidal antibiotic classes, i.e.
first-generation cephalosporins or vancomycin and derivatives when methicillin-resist-
ant S. aureus is a possible pathogen and for patients allergic to 0-lactam drugs (Kaiser,
1986; Anonymous, 1989). Rifampicin (Tshefu et al., 1983) and quinolones (Bouchenaki
et al., 1990; Vaudaux et al., 1990) have proved effective in animal studies. The use of
new macrolides in this setting has not been studied so far. The results of this study
show that the efficacy of S-5556 was similar to that of vancomycin (Bouchenaki et al.,
1990), with a complete protection against infection at 48 h and seven days after
inoculation of the foreign body with lO'cfu of S. aureus. At 24 h after inoculation,
several tissue cage fluids were culture-positive in animals receiving the macrolide, but
only one with vancomycin. This early difference, which had no influence on the final
outcome since all the cages became negative after 48 h, is probably the result of the
slower bactericidal activity of the macrolide. The results obtained with S-5556 were
surprisingly good, especially with regard to the low concentrations of drug measured in
tissue cage fluid. However, these concentrations were maintained above the MIC for
more than 24 h, which is probably an important condition for obtaining a protective
effect (Vaudaux et al., 1990). The excellent penetration of macrolides into polymorpho-
nuclear leucocytes and other phagocytic cells (Miller et al., 1984; Dette & Knothe,
1986) is possibly also a key for success.
In the therapeutic model of chronic foreign body infection, when an erythromycin-
and methicillin-resistant S. aureus isolate was used, S-5556 had significant activity and
yielded results in the range of those obtained previously with vancomycin (Lucet et al.,
1990). As in the prophylaxis study, the concentrations of S-5556 were rather low in the
tissue cage fluid but constantly exceeded the MIC. These promising results were,
however, tempered by the emergence of resistant mutants to high drug levels in 29% of
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the cases. Emergence of resistance to erythromycin during treatment of staphylococcal
infections was reported as early as 1952, shortly after the introduction of this anti-
bacterial agent (Haight & Finland, 1952; Lepper et al., 1953). Although in this model
resistant bacteria were rare after seven days of treatment, a longer course of antibiotics
would probably select mutants and lead to treatment failures. In previous studies on
the treatment of experimental chronic staphylococcal foreign body infections (Lucet
et al., 1990; Chuard et al., 1991a), it was shown that combined regimens (e.g.
vancomycin and rifampicin or fleroxacin and rifampicin) were superior to single drug
therapy, both for efficacy and prevention of emergence of resistant bacteria. Combined
regimens including new macrolides might prove similarly useful in infections caused by
staphylococci.
In conclusion, promising in-vitro and experimental in-vivo data were obtained with a
new 16-membered macrolide against staphylococci, including erythromycin- and
methicillin-resistant strains. This class of antibacterial substances, used alone or in
combination with other antibiotics, deserves further evaluation for this indication.
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